HeartWorks innovative cell therapies rely heavily on our exceptional manufacturing team. This team is essential in executing the intricate processes required to transform patient skin cells into heart muscle cells for our therapies.

Our manufacturing processes have evolved continuously, with the development of robust, FDA-approved procedures crucial for our clinical trials. The achievements of our manufacturing team in 2023 reflect substantial progress. 

This impressive scaling of production capacity highlights the innovation, productivity, and quality of our manufacturing operations. In 2023, our team enhanced batch sizes by increasing the number of vessels used for each sample, proving to be more effective than altering vessel sizes or designs. Additionally, we optimized productivity through refined synchronization of manufacturing activities. Learn more about these activities during the virtual lab tour. 

Looking ahead, as patient numbers and clinical trials increase, we plan to incorporate bioreactors. This will optimize conditions for producing cardiomyocytes, further advancing our ability to meet growing demand and continue delivering groundbreaking therapies.

Our manufacturing team’s dedication is a cornerstone of HeartWorks’ success, enabling us to push the boundaries of medical research and provide cutting-edge treatments to patients. Meet some of the remarkable team members during a virtual lab tour.